Myelodysplastic Syndrome Drugs Global Market Report 2024

Description

“Myelodysplastic Syndrome Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The myelodysplastic syndrome drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Therapeutic Class: Immunomodulatory Drugs; Hypomethylating Agents; Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral; Parenteral
4) By Applications: Original; Generics
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
Companies Mentioned: Amgen Inc.; Celgene Corporation; Otsuka Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Company Limited; Cipla Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Myelodysplastic syndrome (MDS) covers a spectrum of conditions where the bone marrow struggles to produce enough healthy blood cells-red blood cells, white blood cells, and platelets due to irregular cell formation and maturation. This deficiency arises from uncontrolled cell growth and division, causing tissue damage. Medications for myelodysplastic syndrome encompass epoetin alfa, darbepoetin alfa, filgrastim, and other drugs tailored for MDS treatment.

The primary types of drug therapies for myelodysplastic syndrome fall into three categories immunomodulatory drugs, hypomethylating agents, and anti-anemics. Immunomodulatory drugs (IMiDs) constitute a medication class that adjusts or regulates the immune system's response while directly impacting bone marrow cells. The spectrum of syndromes includes refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, and refractory anemia with ringed sideroblasts. These drugs can be administered through various routes such as oral and parenteral methods and serve multiple applications, including original and generic treatments. They are utilized by various end-users, including hospitals, clinics, and ambulatory surgical centers, to address the diverse needs of individuals diagnosed with MDS.

The myelodysplastic syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome drugs market statistics, including myelodysplastic syndrome drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome drugs market share, detailed myelodysplastic syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome drugs industry. This myelodysplastic syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome drugs market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.28 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The increase in historical growth can be ascribed to factors such as an aging demographic, advancements in diagnostic technologies, a rise in cases of chemotherapy-related myelodysplastic syndromes (MDS), greater numbers of cancer survivors, ongoing clinical research, and the continual development of pharmaceuticals.

The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. During the projected period, the anticipated expansion can be linked to the increasing elderly population, advancements in precise therapies, heightened comprehension of disease mechanisms, amplified awareness leading to early detection, and the broadening scope of oncology research. Key trends in this timeframe encompass the optimization of erythropoiesis-stimulating agents, the integration of combination therapies, a heightened emphasis on iron chelation therapy, regulatory endorsements, enhanced market access, and the adoption of patient-centric care models.

The anticipated rise in myelodysplastic syndrome cases is set to drive growth in the market for drugs treating this condition. Myelodysplastic syndrome represents a group of disorders impacting blood cell development in the bone marrow, categorized as a form of blood cancer. Medications for this syndrome aim to modulate the immune system, reducing the need for red blood cell transfusions. Notably, estimates from the American Journal of Managed Care in October 2022 place the prevalence of myelodysplastic syndrome in the USA between 60,000 to 175,000 cases, substantiating the market's growth due to increased incidences.

The burgeoning demand for personalized medicine is expected to be a driving force behind the expansion of the myelodysplastic syndrome drugs market. Personalized medicine involves tailoring treatments based on an individual's unique genetic and medical characteristics. This approach optimizes treatment outcomes and minimizes adverse effects, especially relevant in managing the heterogeneous nature of myelodysplastic syndrome. Notably, in 2022, the FDA's Center for Drug Evaluation and Research greenlit 37 new molecular entities, with the Personalized Medicine Coalition categorizing 12, around 34%, as personalized medicines, emphasizing the market's growth trajectory.

Research and innovation stand out as pivotal trends fueling growth within the myelodysplastic syndrome drug market. Major industry players are focused on pioneering technological advancements to solidify their market positions. For example, in May 2021, Novartis secured FDA fast-track designation for Sabatolimab (MBG453), an investigational immuno-myeloid therapy targeting TIM-3. This innovative therapy, geared towards high-risk myelodysplastic syndromes and acute myeloid leukemia, holds potential for accelerated development and approval, addressing critical medical needs.

Prominent companies operating in the myelodysplastic syndrome drugs sector are intensifying efforts to introduce novel medications, aiming to gain a competitive edge. TIBSOVO, an oral targeted therapy inhibiting the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, is a prime example. Approved for treating adult patients with relapsed or refractory myelodysplastic syndromes (MDS), TIBSOVO represents a significant milestone in the industry. Notably, Servier Laboratories' approval of TIBSOVO by the US FDA in October 2023 marks the first targeted therapy sanctioned for this indication. The approval stems from a pivotal Phase I study evaluating its efficacy in this new application.

In November 2021, Merck & Co., Inc., a US-based pharmaceutical company, acquired Acceleron Pharma Inc. for $11.5 billion. This acquisition aims to expand Merck's pipeline of cardiovascular drugs. Acceleron Pharma Inc. is a US-based biopharmaceutical company involved in developing therapeutics to treat myelodysplastic syndromes and beta-thalassemia.

Major companies operating in the myelodysplastic syndrome drugs market report are Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.

North America was the largest region in the Myelodysplastic syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the myelodysplastic syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The myelodysplastic syndrome drug market consists of sales of drugs such as azacytidine, decitabine, and lenalidomide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11949

1. Executive Summary

2. Myelodysplastic Syndrome Drugs Market Characteristics

3. Myelodysplastic Syndrome Drugs Market Trends And Strategies

4. Myelodysplastic Syndrome Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Myelodysplastic Syndrome Drugs Market Size and Growth

5.1. Global Myelodysplastic Syndrome Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Myelodysplastic Syndrome Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Myelodysplastic Syndrome Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myelodysplastic Syndrome Drugs Market Segmentation

6.1. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Immunomodulatory Drugs
Hypomethylating Agents
Anti-anemics
6.2. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Refractory Cytopenia With Multilineage Dysplasia (RCMD)
Refractory Anemia (RA)
Refractory Anemia With Excess Blasts (RAEB)
Refractory Anemia With Ringed Sideroblasts (RARS)
6.3. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
6.4. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Original
Generics
6.5. Global Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers

7. Myelodysplastic Syndrome Drugs Market Regional And Country Analysis

7.1. Global Myelodysplastic Syndrome Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Myelodysplastic Syndrome Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome Drugs Market

8.1. Asia-Pacific Myelodysplastic Syndrome Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myelodysplastic Syndrome Drugs Market

9.1. China Myelodysplastic Syndrome Drugs Market Overview
9.2. China Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myelodysplastic Syndrome Drugs Market

10.1. India Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myelodysplastic Syndrome Drugs Market

11.1. Japan Myelodysplastic Syndrome Drugs Market Overview
11.2. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myelodysplastic Syndrome Drugs Market

12.1. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myelodysplastic Syndrome Drugs Market

13.1. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myelodysplastic Syndrome Drugs Market

14.1. South Korea Myelodysplastic Syndrome Drugs Market Overview
14.2. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myelodysplastic Syndrome Drugs Market

15.1. Western Europe Myelodysplastic Syndrome Drugs Market Overview
15.2. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myelodysplastic Syndrome Drugs Market

16.1. UK Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myelodysplastic Syndrome Drugs Market

17.1. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myelodysplastic Syndrome Drugs Market

18.1. France Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myelodysplastic Syndrome Drugs Market

19.1. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myelodysplastic Syndrome Drugs Market

20.1. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome Drugs Market

21.1. Eastern Europe Myelodysplastic Syndrome Drugs Market Overview
21.2. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myelodysplastic Syndrome Drugs Market

22.1. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myelodysplastic Syndrome Drugs Market

23.1. North America Myelodysplastic Syndrome Drugs Market Overview
23.2. North America Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myelodysplastic Syndrome Drugs Market

24.1. USA Myelodysplastic Syndrome Drugs Market Overview
24.2. USA Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myelodysplastic Syndrome Drugs Market

25.1. Canada Myelodysplastic Syndrome Drugs Market Overview
25.2. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myelodysplastic Syndrome Drugs Market

26.1. South America Myelodysplastic Syndrome Drugs Market Overview
26.2. South America Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myelodysplastic Syndrome Drugs Market

27.1. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myelodysplastic Syndrome Drugs Market

28.1. Middle East Myelodysplastic Syndrome Drugs Market Overview
28.2. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myelodysplastic Syndrome Drugs Market

29.1. Africa Myelodysplastic Syndrome Drugs Market Overview
29.2. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myelodysplastic Syndrome Drugs Market Competitive Landscape And Company Profiles

30.1. Myelodysplastic Syndrome Drugs Market Competitive Landscape
30.2. Myelodysplastic Syndrome Drugs Market Company Profiles
- 30.2.1. Amgen Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Celgene Corporation
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Otsuka Pharmaceutical Co. Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Takeda Pharmaceutical Company Limited
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Cipla Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Myelodysplastic Syndrome Drugs Market Competitive Benchmarking

32. Global Myelodysplastic Syndrome Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Drugs Market

34. Myelodysplastic Syndrome Drugs Market Future Outlook and Potential Analysis

34.1 Myelodysplastic Syndrome Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Myelodysplastic Syndrome Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Myelodysplastic Syndrome Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer